Using microRNA (miRNA) expression array, we identified that miR-7 was deregulated in colorectal cancer (CRC). We studied the biological role and molecular target of miR-7 in CRC. miR-7 was downregulated in six out of seven colon cancer cell lines. Ectopic expression of miR-7 suppressed colon cancer cell proliferation (Po0.05), induced apoptosis (Po0.05) and caused cell-cycle arrest in G1 phase (Po0.05). The tumor suppressive function of miR-7 was further confirmed in nude mice (Po0.05). The 3 0 -untranslated region (3 0 UTR) of Yin Yang 1 (YY1) mRNA contains an evolutionarily conserved miR-7 binding site using in silico searches, luciferase reporter assay and western blot analysis confirmed that miR-7 directly bound to YY1 3 0 UTR to negatively regulate the protein expression of YY1 in colon cancer cell lines HCT116 and LOVO. Intriguingly, knock-down of YY1 in three colon cancer cell lines (HCT116, LOVO and DLD1) consistently suppressed cell proliferation (Po0.01) and induced apoptosis (Po0.01), indicating the opposite functions of miR-7 and YY1 in CRC. Consistent with these data, ectopic expression of YY1 promoted cell growth by increasing proliferation (Po0.01) and suppressing apoptosis (Po0.001). The tumorigenic ability of YY1 was further confirmed in vivo in xenograft-nude mouse model (Po0.01). In addition, pathway analyses revealed that the oncogenic effect by YY1 was associated with inhibiting p53 and modulating its downstream effectors p15, caspase cascades and C-Jun, and activating Wnt signaling pathway through activating b-catenin, anti-apoptotic survivin and fibroblast growth factor 4. Furthermore, multivariate analysis revealed that patients with YY1 protein high expression had a significant decrease in overall survival, and Kaplan-Meier survival curves showed that these patients had significantly shorter survival than others (Po0.0001). In conclusion, MiR-7 is a novel miRNA with tumor suppressive function in colon cancer by targeting oncogenic YY1. YY1 promotes colon cancer growth through inhibiting p53 and promoting Wnt signaling pathways and serves as an independent prognostic biomarker for CRC patients.
INTRODUCTION
Colorectal cancer (CRC) is the third most common malignancy worldwide. 1 The formation of CRC is a multistep process that can arise from accumulation of genetic and epigenetic changes. 2 CRC tumorigenesis can be driven by specific molecular alterations with functional effects in pro-survival signaling pathways such as p53 pathway, Wnt-b-catenin pathway, EGFR (epidermal growth factor receptor)-MAPK (mitogen-activated protein kinase) pathway, PI3K (phosphatidylinositol 3-kinase) pathway, nuclear factor-kappa B (NF-kB) pathway and activator protein 1 (AP-1) pathway. 3 Of particular interest, non-coding RNAs including antisense RNA, small nucleolar RNA and microRNA (miRNA) have recently emerged as critical regulators in these signaling cascades, and miRNA has received the greatest attention due to its frequent deregulation in cancer. 4 miRNAs are a group of endogenous small non-coding RNAs (19-25 nucleotides) that participate in the regulation of gene expression at post-transcriptional level through direct interaction with the 3 0 -untranslated regions (3 0 UTRs) of the target mRNAs. They have important roles in diverse cellular processes including cell proliferation, differentiation and apoptosis. 5 To date, over 100 miRNAs have been implicated in CRC, 6 wherein a specific group including miR-17-3p, miR-17-92, miR-21 and miR-92a is associated with clinical outcomes. 7, 8 Despite the evident correlation with CRC, only a limited number of miRNAs such as let-7, 9 miR-143, 10 miR-34a, 11 miR-137 12 and miR-21 13 have been characterized for their specific functional mechanisms. In this study, miR-7 was identified to be significantly downregulated in CRC by miRNA expression array, and acts as a tumor suppressor in CRC according to our novel data. miR-7 exerts its role by directly inhibiting the oncogenic protein YY1, resulting in differential regulations of the functional units in p53 and Wnt pathways with significant impact on cancer development. Finally, we revealed that YY1 was associated with poor survival of CRC patients.
RESULTS

miR-7 is downregulated in CRC and acts as a tumor suppressor
We performed miRNA expression profiling on two paired CRC tumors and identified a panel of differentially expressed miRNAs specific for CRC. In particular, we found that miR-7 was downregulated up to 4.1-fold in both CRC tumors compared with the corresponding normal tissues (Supplementary Figure 1 ; Supplementary Table 1) . miR-7 was downregulated in six out of seven colon cancer cell lines compared with normal colon tissues (Supplementary Figure 2) . The downregulation of miR-7 in tumors suggested that it could have a role in the development of CRC. To verify the effect of miR-7 in CRC, we first examined the impacts of excessive miR-7 on the proliferation of human colon cancer cells. When compared with control precursor, miR-7 precursor caused a significant reduction in cell viability in both HCT116 and LOVO cells (Po0.05) (Figure 1a ). Further analysis by colony formation assay showed that HCT116 cells transfected with miR-7 precursor formed 35% less colonies than the ones transfected with control precursor (Po0.01) (Figure 1b) . Such growth inhibitory effect by miR-7 precursor in HCT116 cells and LOVO cells was accompanied with an increase in early-apoptotic population (Po0.05) (Figure 1c) , and a delay of G0/G1-to S-phase transition (Po0.05) (Figure 1d ). These overall results support the notion that miR-7 acts as a tumor suppressor in CRC through induction of apoptosis and regulation of early cell-cycle checkpoint. In vivo experiment was performed to verify the function of miR-7 in tumorigenicity. We found that the growth of xenograft tumors of miR-7-transfected HCT116 cells in nude mice was significantly slower compared with the miR control-transfected cells (Po0.05) ( Figure 1e ). Moreover, the mean tumor weight in miR-7-transfected nude mice was significantly lower as compared with the control mice (Po0.05) (Figure 1e ).
miR-7 targets the 3 0 UTR of YY1 for translational repression
We next sought to identify the molecular binding target of miR-7 by in silico searches using two different prediction algorithms miRanda and TargetScan. We found that the 3 0 UTR of human YY1 contains a putative binding site for miR-7. To verify whether miR-7 directly binds to the 3 0 UTR of YY1 and causes translational inhibition, we constructed two plasmids encoding a firefly luciferase transcript with either wild-type or mutant 3 0 UTR of YY1 (Figure 2a) , and evaluated their respective expression levels after incubation with either control or miR-7 precursor. Our results showed that miR-7 inhibited the expression of the transcript containing wild-type 3 0 UTR of YY1; by contrast, miR-7 caused no significant changes to the expression of the transcript containing mutant 3 0 UTR of YY1 (Figure 2b; Supplementary Figure 3 ). These data demonstrate a specific inhibitory effect of miR-7 on the 3 0 UTR of YY1 through direct interaction. miR-7 is a negative regulator of YY1 in human CRC Given the repression effect of miR-7 on the luciferase transcript containing YY1 3 0 UTR, we speculated that miR-7 might regulate the expression of endogenous YY1 in a similar manner. To test this hypothesis, we examined the relative abundances of miR-7 and YY1 in six human CRC cell lines by real-time PCR and western blot (Figure 2c ), respectively. The resulting quantification showed that miR-7 and YY1 exhibited bipolar and asymmetric expression in most tested cell lines (Figure 2c ), suggesting an inverse correlation between miR-7 and YY1 in CRC (r ¼ À 0.37). To examine the potential negative regulatory effect of miR-7 on endogenous YY1, we transfected miR-7 precursor or control vector into HCT116 and LOVO cells (which displayed lower level of miR-7 among the tested cell lines). In comparison with miR control, miR-7 exerted no discernible effect on YY1 mRNA, but caused B30% reduction in YY1 protein in both cell lines (Figure 2d ). To further investigate whether miR-7 regulates endogenous YY1, HCT116 cells were co-transfected with miR-7 and PCMV-Flag-YY1 that lack of 3 0 UTR sequence, or co-transfected with miR control and PCMVFlag-YY1. The expression of YY1 was not affected by miR-7 in the lack of YY1 3 0 UTR sequence as demonstrated by western blot (Figure 2e ), indicating a direct interaction between miR-7 and YY1 at its 3 0 UTR region. Moreover, when HCT116 cells were transfected with antagomiR-7 which blocked the function of miR-7 or antagomiR control, YY1 protein level was elevated in antagomiR-7-transfected HCT116 cells compared with antagomiR control-transfected cells (Figure 2e ), further confirming the interaction between miR-7 and YY1. This information, together with the identified interaction between miR-7 and YY1 3 0 UTR (Figures 2a and b) , indicates that expression of endogenous YY1 is negatively regulated by miR-7 at translational but not at transcriptional level.
YY1 is upregulated in CRC with an oncogenic function We examined the mRNA expression of YY1 in 75 paired tumor and adjacent normal primary CRC samples. We found that YY1 was significantly upregulated in tumor tissues compared with the adjacent normal tissues (Po0.001) (Figure 2f ). Upregulation of YY1 was also observed in nine colon cancer cell lines compared with the normal colon tissues (Figure 2g ), inferring aberrant gene expression of YY1 in CRC.
Based on the consistently high expression of YY1 in primary CRC tissues and cell lines, we investigated whether YY1 contributes to the growth of CRC cells. To this end, we abolished YY1 expression in DLD1, HCT116 and LOVO cells by transient transfection of YY1 siRNA (si-YY1). Knock-down of YY1 was confirmed by both RT-PCR and western blot (Figure 3a ), which caused a significant decrease in cell viability in HCT116 (Po0.01), DLD1 (Po0.001) and LOVO (Po0.001) (Figure 3b ). The inhibitory effect on colon cancer cell growth was confirmed by colony formation assay. The colonies formed in HCT116 cells with stable knock-down of YY1 using shRNA displayed 430% reduction compared with control cells (Po0.01) (Figure 3c ). Additionally, Ki-67 staining showed a decreased proliferation index in sh-YY1-transfected HCT116 cells compared with vector-transfected cells (P ¼ 0.001) (Figure 3c ). On the other hand, ectopic expression of YY1 in SW480 cells caused a significant increase in cell viability (Po0.001) (Figure 3d ). Collectively, these results suggested that YY1 exhibits growth promotion ability in colon cancer cells.
We also examined the contribution of apoptosis to the observed growth promotion of YY1-transfected cells using flow cytometry with Annexin V and 7-amino-actinomycin (7-AAD) double staining. Our results showed that YY1 knock-down caused significant increase in the numbers of early-apoptotic cells in HCT116 (Po0.01), DLD1 (Po0.01) and LOVO (Po0.01) (Figure 4a ). This effect was further confirmed by a gain-of-YY1-function assay that ectopic expression of YY1 significantly reduced the proportion of early-apoptotic cells in SW480 (Po0.001) (Figure 4a ). To elucidate the molecular basis of apoptosis, we examined the pro-apoptosis mediators including the active form of caspase-3, caspase-7, caspase-9 and nuclear enzyme poly (ADPribose) polymerase (PARP) and anti-apoptosis gene survivin in the si-YY1-transfected HCT116 and LOVO cells. Knock-down of YY1 increased the protein levels of the active form of caspase-3, caspase-7, caspase-9 and PARP, but reduced survivin in both cell lines (Figure 4b ), adding further evidence for the anti-apoptosis effect of YY1 in CRC.
To confirm the tumor promotion effect of YY1 in CRC, we evaluated the impact of YY1 on the growth of colon cancer cells in nude mice in vivo. The tumor growth curve of HCT116 stably transfected with sh-YY1 or control vector in nude mice was shown in Figure 5a . The tumor growth was significantly slower in sh-YY1-transfected nude mice as compared with the vector control mice (Po0.01) (Figure 5a ). At the end of experiments, xenograft tumors were isolated and the mean tumor weight was significantly lower in sh-YY1-transfected nude mice as compared with the control mice (Po0.05) (Figure 5a ). These results further confirmed the oncogenic role of YY1 in CRC tumorigenesis.
miRNA-7 and YY1 in colorectal cancer N Zhang et al YY1 promotes CRC tumorigenesis through p53-and Wnt-signaling pathways To elucidate the molecular mechanism of the YY1-associated CRC tumorigenesis, we examined the functional effect of YY1 in several important cancer pathways including p53, NF-kB, AP-1, SRE (serum responsive element) and TOPFlash (Wnt signaling) by luciferase reporter activity assay. Ectopic expression of YY1 inhibited p53 luciferase reporter activity, but increased TOPFlash reporter activity in both HCT116 and LOVO cells (Figure 5b ), while no significant activity changes in other pathway reporters were observed. Moreover, knock-down of YY1 induced p53 protein level, but reduced active b-catenin protein level in both HCT116 and LOVO cell lines (Figure 5c ), indicating the opposite roles of YY1 in p53-and Wnt-signaling pathways. To further determine the downstream mediators of p53-and Wnt-signaling pathways derived by YY1, gene expression profiles on HCT116, LOVO and SW480 cells with upregulation or downregulation of YY1 were analyzed by p53-and Wnt-signaling pathway cDNA array, respectively. A total of 20 candidates were identified as the regulation targets of YY1 (Table 1 ). In the p53-dependent cascade, YY1 negatively regulated PARP, p53, E2F1, GML1, Caspase 3, Caspase 7 and Caspase 9, but positively regulated MCL1 (myeloid cell leukemia sequence 1) and c-Jun. In the Wnt-associated pathway, YY1 displayed an inverse correlation with CSNK1A1 (casein kinase 1 alpha 1), CTNNBIP1 (beta-catenin interacting protein 1) and SFRP1 (secreted frizzled-related protein 1), but a positive correlation with Wnt1, Wnt3a, Wnt4, FZD4 (frizzled-4), bcatenin, FGF4 (fibroblast growth factor 4), survivin and FOXN1 (forkhead box protein N1). Collectively, a model was established to illustrate the differential regulations of p53 and Wnt pathway members by YY1, and the respective functional consequences in CRC tumorigenesis (Figure 5d ).
YY1 is an independent predictor of poor outcome of CRC patients To examine the clinical implication of YY1 in CRC, we analyzed the expression of YY1 in a CRC tissue microarray (TMA) comprising 212 pairs of CRC tissues and adjacent normal tissues. As shown by immunohistochemical staining, specific nuclear expression of YY1 was detected in tumor cells of CRC tissues but not in those of adjacent normal tissues (Figure 6a ). We revealed that upregulation of YY1 in CRC tissues was positively related to lymph-node metastasis (P ¼ 0.003), distant metastasis (P ¼ 0.01), TNM (tumor, nodes, metastasis) stage (Po0.001) and survival (Figure 6b; Supplementary Table 2) . When samples were dichotomized to tumors with cutoff score values of 67.5, Kaplan-Meier analysis showed that the mean survival time for 87 CRC patients with high expression of YY1 was 66 ± 7.48 months, compared with 83 ± 4.92 months for 125 CRC patients with low or no YY1 expression (Po0.0001, log-rank test) (Figure 6c ). In univariate Cox regression analysis, the tumor stage was a significant prognostic factor (Po0.0001) ( Table 2) . Moreover, YY1 high expression was associated with an increased risk of cancer-related death (relative risk (RR), 2.777; 95% confidence interval (CI), 1.663-4.638; Po0.0001) ( Table 2 ). After adjusting the potential confounding factors, multivariate Cox regression analysis demonstrated that YY1 expression was an independent predictor for the poor survival of CRC patients (RR, 1.986, 95% CI, 1.144-3.446, Po0.05) ( Table 2) .
DISCUSSION
Colorectal carcinogenesis is a multistep process mediated by a complex cascade of molecular events monitoring genome stability and cell proliferation.
14 In this study, we report that miR-7 is a novel miRNA in CRC with tumor suppressive functions of reducing cell proliferation, increasing cell apoptosis, activating early cellcycle checkpoint in vitro and diminishing xenograft tumor growth in nude mice. We identified that miR-7 is a negative regulator of YY1 through direct interaction with the 3 0 UTR of YY1 to cause translational inhibition. This finding is significant as our data showed that YY1 is an oncogenic protein with evident contribution in the survival of CRC cells, which is in accord with the high expression of YY1 in both clinical CRC tissues and cultured CRC cell lines. Furthermore, we revealed that YY1 exerts oncogenic function by inducing cell proliferation and suppressing cell apoptosis through regulating p53-and Wnt-signaling pathways and their associated effectors. The pivotal role of YY1 in promoting cancer development is supported by the in vivo evidence that tumors without YY1 expression displayed a dramatic reduction in growth rate. Of particular importance, we revealed that YY1 expression is positively associated with poor survival of CRC patients. This collective information is vital to understand the molecular basis of CRC formation, and it provides clinical implication of YY1 in prediction of patient outcome.
In the cancer-associated miRNAs identified to date, miR-7 has emerged as a robust tumor suppressor with diverse targets in multiple types of cancers. [15] [16] [17] However, the effect of miR-7 and its molecular target in CRC are still largely unknown. Here, we report a novel pathway that miR-7 inhibits the expression of YY1 which in turn alters the p53-and Wnt-dependent signaling in CRC cells. Despite impact of miR-7 on distinct molecular cascades in individual cancer types, the functional effects are consistent resulting in suppression of tumorigenesis as evident by reduced cell viability, activated cell-cycle arrest, impaired cell motility or decreased anchorage-independent growth. These concordant results establish the critical regulatory role of miR-7 in CRC development and suggest that miR-7 may serve as a potential therapeutic target. miR-7 is one of the most downregulated miRNAs in our miRNA array data on colon cancers (Supplementary Table 1 ). Although miR-7 is verified to be downregulated in colon cancer cell lines as compared with normal colon tissues (Supplementary Figure 2) , the downregulation of miR-7 is not demonstrated in primary CRC samples (data not shown). This discrepancy may be explained by the contamination of normal cells in the tumor tissues, which warrants further evaluation by miR-7 in situ hybridization in primary colon cancer tissues and their adjacent normal controls in our future study.
The miR-7 downstream target YY1 is a multifunctional protein that can act as a transcriptional repressor, an activator, or an initiator element, thereby has pivotal roles in a multitude of cellular processes, such as development, differentiation, proliferation and apoptosis. Deregulation of YY1 expression has been associated with oncogenesis and upregulation of YY1 has been reported in different cancers. [18] [19] [20] Nevertheless, the exact roles of YY1 in cancer development remain controversial. For instance, YY1 can function as a tumor suppressor by silencing the expression of viral oncogenes in human papilloma virus-infected cervical cancer cells. 21, 22 On the contrary, YY1 can promote tumorigenesis by upregulating proto-oncogene ERBB2 (human epidermal growth factor receptor 2) in breast cancer cells. 18 In this study, we show that YY1 is frequently upregulated in human CRC tumor tissues as well as CRC cell lines. We provide in vitro and in vivo evidence that YY1 is an oncogenic protein in CRC cells with evident roles in promoting cell survival and inhibiting cell apoptosis. More specifically, we show that these functional consequences are mediated through p53-and Wnt-mediated pathways.
The transcription factor p53 is a well-characterized tumor suppressor that protects cells against genetic insults through multiple mechanisms, such as activation of DNA repair cascades, induction of cell-cycle checkpoint and initiation of programmed cell death. 23 We observed an inverse correlation between YY1 and p53 in CRC cells. Furthermore, we showed that YY1 exerts an inhibitory effect on E2F1 and PARP that serve as a positive regulator of p53, 24, 25 indicating that YY1 can modulate p53 expression through multiple mechanisms. In addition to the upstream factors of p53, YY1 can also regulate the corresponding downstream components. We found that YY1 expression is miRNA-7 and YY1 in colorectal cancer N Zhang et al positively related to the proto-oncogene c-Jun that contributes to cell growth and G1-to-S-phase progression. 26 On the other hand, YY1 stimulates the expression of anti-apoptotic MCL1, 27 but suppresses the expression of pro-apoptotic caspase 3, caspase 7, caspase 9 and GML1 28, 29 (Figure 4b ). These differential regulations respectively contribute to attenuation of programmed cell death and increased cell proliferation, suggesting that YY1 facilitates the survival of CRC cells. In line with our findings, a study identified the direct interactions of YY1 with Hdm2 and p53, and showed that YY1 stimulates the Hdm2-dependent ubiquitylation and degradation of p53. 30 Moreover, another study reported that YY1 regulates the activity and stability of p53 by inhibiting its interaction with the co-activator p300, and by enhancing its interaction with the negative regulator Mdm2. 31 In this regard, the oncogenic effect of YY1 in colorectal carcinogenesis may be partly related to inhibition of p53-signaling pathway.
Apart from interacting with p53-associated proteins, YY1 also participates in Wnt signaling cascades. Here, we elucidated the role of YY1 in Wnt pathway by examining the effect of YY1 on additional Wnt-associated members in CRC cells. We found that YY1 is a negative regulator of the Wnt antagonists CSNK1A1, 32 
CTNNBIP1
33 and SFRP1. 34 Conversely, YY1 causes upregulation of the Wnt-initiating components Wnt1, Wnt3a, Wnt4, FZD4 and bcatenin 35 ( Table 1 ; Figure 5d ). These data are in line with a recent finding that YY1 suppresses a Wnt inhibitor (deletion mutant of LEF-1 (lymphoid enhancer-binding factor 1)). 36 These data clearly indicate that YY1 acts to promote Wnt signaling in CRC. In addition, our results showed that YY1 expression is positively associated with the Wnt-dependent proteins FGF4 and Survivin that serve as apoptosis inhibitor, 37, 38 and FOXN1 that contributes to cell differentiation and proliferation. 39, 40 These results, when combined with the functions of YY1 in p53 pathway, strongly implicate a stimulatory role of YY1 in CRC tumorigenesis through Wnt and p53-signaling cascades.
To determine the clinical relevance of YY1 in CRC in vivo, we examined the protein expression of YY1 in 212 primary CRCs with complete follow-up data. We found that the increased staining of YY1 in CRC tissues was significantly correlated with advanced clinical stage and tumor metastasis, suggesting that overexpression of YY1 in CRC may facilitate the invasive/ metastatic phenotype. In this connection, overexpression of YY1 in CRC was demonstrated as an independent predictor of poorer survival of CRC patients. These findings provided additional evidence for the oncogenic role of YY1 in the development of CRC.
In conclusion, miR-7 is a novel miRNA with tumor suppressive function in CRC through directly suppressing oncogenic YY1. YY1 has pivotal roles in promotion of cell proliferation and inhibition of cell apoptosis through regulating p53 and Wnt pathways, which in turn facilitates cancer growth and development. Moreover, YY1 is 
RNA extraction, semi-quantitative RT-PCR and real-time PCR analyses
Total RNA was extracted from cell pellets or tissues using QIAzol reagent (Qiagen, Valencia, CA, USA) and miRNeasy mini kit (Qiagen). Total RNA was reverse-transcribed by High Capacity cDNA Reverse Transcription Kit (Invitrogen) and MultiScribe (Applied Biosystems, Foster City, CA, USA) with miRNA-specific stem-loop reverse-transcription (RT) primer. Semi-quantitative RT-PCR was performed using Hot-star DNA polymerase (Invitrogen). Real-time PCR was performed using SYBR Green master mixture (Applied Biosystems) on HT7900 system (Applied Biosystems). The expression level of mature miR-7 was quantified by TaqMan microRNA assays (Applied Biosystems).
Cell viability assay
Cell viability was measured by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (Promega, Madison, WI, USA). In all, 3 Â 10 3 cells were seeded in 96-well plate, 20 ml of reaction solution containing 333 mg/ml MTS and 25 mM phenazine ethosulfate was added to cells in 100 ml culture medium, the mixture was incubated at 37 1C for 1 h and then measured for optical density value at 490 nm.
Flow cytometry
For cell-cycle analysis, cells were fixed in 70% ethanol and stained with propidium iodide (BD Pharmingen, San Jose, CA, USA). The stained cells were sorted by FACSCan (BD Biosciences, Franklin Lakes, NJ, USA) and the acquired cell-cycle profiles were analyzed by WinMDI ver 2.9 software (Scripps Research Institute, La Jolla, CA, USA). For apoptosis analysis, cells were stained with Annexin V (APC-conjugated) and 7-AAD (BD Biosciences), then analyzed by fluorescence-activated cell sorting using FACScan (BD Biosciences). Cell populations were classified as viable (Annexin V negative, 7-AAD negative), early apoptotic (Annexin V positive, 7-AAD negative), late apoptotic (Annexin V positive, 7-AAD positive) or necrotic (Annexin V negative, 7-AAD positive).
Colony formation assay
After 48 h of transfection, cells were collected and seeded (2 Â 10 3 /well) in 6-well plate for 10-14 days. Colonies (X50 cells/colony) were then counted after being fixed with 70% ethanol and stained with crystal violet solution.
Ki-67 staining Luciferase reporter assay
The sense and antisense oligonucleotides (2 mg) containing wild-type or mutated YY1 3 0 UTR were annealed in 30 mmol/l HEPES buffer containing 100 nmol/l potassium acetate. The annealed oligonucleotides were respectively cloned into the pMIR-report luciferase vectors (Ambion, Inc.) between Hindlll and Spel restriction sites. HCT116 (1 Â 10 5 cells/well) in 24-well plate was co-transfected with 20 or 40 nM/l miRNA precursor, pMIR-report luciferase plasmid (195 ng/well) and pRL-CMV vector (5 ng/well). To investigate the signaling pathways modulated by YY1, a series of signaling pathway luciferase reporters including p53-luc (14 Â p53 binding sites), NF-kB-luc (5 Â NF-kB binding sites), AP1-luc (7 Â AP1 binding sites), SRE-luc (5 Â SRE binding elements) and TOPFlashluc (4 Â TCF binding sites) were examined. Colon cancer cells were cotransfected with pRL-CMV vector (5 ng/well), pCMV-Flag or pCMV-YY1. Cells were harvested at 48 h post transfection and the ratio of firefly to Renilla luciferase activity was analyzed by the dual-luciferase reporter assay system (Promega). 
Western blot
Total protein was extracted and protein concentration was measured by the DC protein assay method of Bradford (Bio-Rad, Hercules, CA, USA). Protein samples (30 mg each) were separated on 10% Bis/Tris-polyacrylamide gel by electrophoresis and blotted onto nitrocellulose membranes (GE Healthcare, Piscataway, NJ, USA). Blots were stained with primary antibodies overnight at 4 1C and secondary antibody for 1 h at room temperature. Proteins were visualized using ECL Plus Western blotting Detection Reagents (GE Healthcare).
In vivo tumorigenicity assays
To evaluate the effect of miR-7 in tumorigenicity, HCT116 cells (1.5 Â 10 6 cells) transfected with miR-7 precursor or control miRNA were injected subcutaneously into the dorsal flank of 4-week-old female Balb/c nude mice (5/group) at day 0. Tumor diameter was measured every 3 days before harvest after 3 weeks.
To evaluate the effect of YY1 in tumorigenicity, HCT116 cells (1.5 Â 10 6 cells) transfected with shYY1 or pBabe control vector were injected subcutaneously into the dorsal left flank of 4-week-old male Balb/c nude mice (4/group). Tumor diameter was measured every 2 days for 3 weeks. Tumor volume (mm ) was estimated by measuring the longest and shortest diameter of the tumor. All experimental procedures were approved by the Animal Ethics Committee of the Chinese University of Hong Kong.
TMA immunohistochemistry
The TMA blocks covering 212 paired CRC and matched normal tissues were cut into 5-mm sections and processed for immunohistochemistry. TMA blocks were incubated with anti-YY1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or normal rabbit IgG (negative control). Immunostaining was performed using the Envision System with diaminobenzidine (Dako, Hong Kong, China).
Statistical analysis
The results were expressed as mean ± s.d. Statistical analysis was performed using the SPSS statistical software package (standard version 13.0, SPSS Inc., Chicago, IL, USA). Mann-Whitney U test or Student's t-test was performed to compare the variables of two groups. The difference in cell viability and the nude mice's tumor growth rate between the two groups was determined by repeated-measures analysis of variance. Receiver operating characteristic curve analysis was applied to determine the cutoff scores of YY1 expression in TMA. The correlation between clinicopathological features of CRC patients and YY1 expression was analyzed by w 2 test. Crude relative risks (RRs) of death associated with YY1 expression and other predictor variables were estimated by univariate Cox proportional hazards regression model. Then multivariate Cox model was constructed to estimate the adjusted RR for YY1 expression. Overall survival curves in relation to YY1 expression was evaluated by the KaplanMeier survival curve and the log-rank test. Value of Po0.05 was taken as statistical significance. miRNA-7 and YY1 in colorectal cancer N Zhang et al
